 | Up a level |
Koschmieder, Steffen, Isfort, Susanne, Heidel, Florian H., Hochhaus, Andreas, Becker, Heiko, Jost, Philipp J., Schafhausen, Philippe, Griesshammer, Martin, Wolleschak, Denise, Haenel, Mathias, Goethert, Joachim R., Teichmann, Lino L., Sockel, Katja, Radsak, Markus P., Reiter, Andreas, Doehner, Konstanze, Balleisen, Sebastian, Jaekel, Nadja, von Bubnoff, Nikolas, Stegelmann, Frank, Gezer, Deniz, Kortmann, Maike, Frank, Julia, Hellmich, Martin and Bruemmendorf, Tim H. (2022). Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN). Blood, 140. S. 1790 - 1794. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020